Clinical trials: Patients With Type 2 Diabetes
Diabetes Mellitus, Non-Insulin-Dependent
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug…
- Trial name
- NCT01105429
- Testing
- BMS-820132
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 2
Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.
- Trial name
- NCT00094991
- Testing
- Muraglitazar
- Where
- 2 sites in United States, Italy
- Volunteers
- 42 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 2
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar.
- Trial name
- NCT03341312
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin
Primary objective: To show an improvement in HbA1c control after 4 months of treatment with insulin glargine + Oral Anti Diabetic (OAD) in patients previously uncontrolled on premixed insulin (with OAD) Secondary objective…
- Trial name
- OPTIMIZATION (NCT00693771)
- Testing
- Insulin Glargine
- Where
- China
- Volunteers
- 313 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with…
- Trial name
- NCT01214239
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri Lanka
This study is conducted in Asia. The aim of this non-interventional study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in Sri Lanka.
- Trial name
- DiabCare Asia (NCT01957592)
- Testing
- No treatment given
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast
This study is designed to look at how best to start and then gradually intensify (as needed) the insulin lispro premix regimen in type 2 diabetes patients who consume a light breakfast.
- Trial name
- NCT00664534
- Testing
- Insulin Glargine, Insulin Lispro Premix (mid-mixture and low-mixture)
- Where
- 27 sites in Canada, Egypt and 6 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company
Complications of Diabetes Mellitus, Diabetes Mellitus
Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin
Considering that, Diacerein is on the market for 16 years being used continuously in elderly patients with osteoarthritis without experience significant side effects, and considering the anti-hyperglycemic effect and the…
- Conditions
- Complications of Diabetes Mellitus, Diabetes Mellitus, Diabetes Mellitus, Type 2
- Trial name
- NCT03208309
- Testing
- Diacerein
- Where
- 3 sites in Brazil
- Volunteers
- 40 people
- Sponsor
- ANS Pharma
Diabetes Mellitus, Type 2
Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanon
The study is investigating Ryzodeg®,a medication prescribed to patients with type 2 diabetes mellitus.The study is being carried out to investigate the effect of Ryzodeg® on the change of glycated haemoglobin levels and other…
- Trial name
- NCT04892069
- Testing
- Insulin Degludec/Insulin Aspart
- Where
- Lebanon
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.
- Trial name
- NCT00998881
- Testing
- Teneligliptin 20 mg
- Where
- Japan
- Volunteers
- 203 people
- Sponsor
- Tanabe Pharma Corporation
Type 1 Diabetes, Type 2 Diabetes
To Evaluate the Efficacy and Safety of the Insulin Patch Pump System in Patients With Diabetes.
Patients will be enrolled and randomly assigned to either the test group or the control group for short-time intensive insulin therapy in inpatient setting.
- Trial name
- NCT07403565
- Testing
- Insulin Patch Pump System, Minimed 700
- Where
- 5 sites in China
- Volunteers
- 161 people
- Sponsor
- Suzhou Hechun Medical Technology Co., Ltd.
Diabetes Mellitus, Type 2
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
This is an 80-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not…
- Trial name
- NCT00138619
- Testing
- vildagliptin
- Where
- 2 sites in United States, Germany
- Volunteers
- 478 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia
This observational study is a non-interventional, multi-center, prospective observational study aimed at tracking the efficacy and safety of Envlo or Envlomet SR tablets for 24 weeks in patients with type 2 diabetes and…
- Trial name
- NCT06647888
- Testing
- Envlo Tablet, Envlomet SR Tablet
- Where
- South Korea
- Volunteers
- 12,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertension
Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria
To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with type 2 diabetes and albuminuria.
- Trial name
- NCT02807974
- Testing
- CS-3150
- Where
- Japan
- Volunteers
- 51 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Hypertension, Type 2 Diabetes
Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes
Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit.
- Trial name
- NCT00803660
- Where
- 19 sites in Vietnam
- Volunteers
- 1,060 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Indian Phenotype Registry
This study is a non-interventional, multicentre observational study to be conducted at 1000 sites in India. The study targets to enrol approx. 50000 patients with approx. 50 patients per site.
- Trial name
- IP Registry (NCT03363594)
- Where
- 197 sites in India
- Volunteers
- 40,000 people
- Sponsor
- AstraZeneca
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Diabetes (DM), Diabetes Mellitus Type 2
Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone
This Phase 3 Bridge study is designed to evaluate the efficacy and safety of IN-B00009 Injection in Patients with T2DM Inadequately Controlled by Diet and Exercise Alone
- Trial name
- NCT07308184
- Testing
- IN-B00009
- Volunteers
- 110 people
- Sponsor
- HK inno.N Corporation
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of Teneligliptin in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration and to evaluate the safety and efficacy of Teneligliptin…
- Trial name
- NCT02081599
- Testing
- Teneli (Teneligliptin), Insulin
- Where
- Japan
- Volunteers
- 148 people
- Sponsor
- Tanabe Pharma Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.